<DOC>
	<DOC>NCT03006445</DOC>
	<brief_summary>The purpose of this study is confirmatory investigation of safety and efficacy of FYU-981 administered orally to hyperuricemic patients with and without gout for 34 or 58 weeks by the method of multicenter, open label and ascending dose regimen.</brief_summary>
	<brief_title>Study of FYU-981 in Hyperuricemia With or Without Gout</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<criteria>Hyperuricemic or gout patients Serum urate level: &gt;= 7.0mg/dL in patients with history of gout, or &gt;= 8.0mg/dL in patients with hypertension, diabetes or metabolic syndrome, or &gt;= 9.0mg/dL Gouty arthritis within two weeks before start of study treatment Secondary hyperuricemia HbA1c: &gt;= 8.4% Uric acidoverproduction type in the classification of hyperuricemia History of, clinically significant cardiac, hematologic and hepatic disease Kidney calculi or clinically significant urinary calculi eGFR: &lt; 30mL/min/1.73m^2 Systolic blood pressure: &gt;= 180 mmHg Diastolic blood pressure: &gt;= 110 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>